Dept. of Physiology and Cell Biology, College of Medicine and Public Health, The Ohio State Univ., 304 Hamilton Hall, 1645 Neil Ave., Columbus, OH 43210, USA.
Am J Physiol Gastrointest Liver Physiol. 2013 May 15;304(10):G855-63. doi: 10.1152/ajpgi.00421.2012. Epub 2013 Mar 21.
Serotonin [5-hydroxytryptamine (5-HT)] is released from enterochromaffin cells in the mucosa of the small intestine. We tested a hypothesis that elevation of 5-HT in the environment of enteric mast cells might degranulate the mast cells and release mediators that become paracrine signals to the enteric nervous system, spinal afferents, and secretory glands. Western blotting, immunofluorescence, ELISA, and pharmacological analysis were used to study expression of 5-HT receptors by mast cells in the small intestine and action of 5-HT to degranulate the mast cells and release histamine in guinea pig small intestine and segments of human jejunum discarded during Roux-en-Y gastric bypass surgeries. Mast cells in human and guinea pig preparations expressed the 5-HT1A receptor. ELISA detected spontaneous release of histamine in guinea pig and human preparations. The selective 5-HT1A receptor agonist 8-hydroxy-PIPAT evoked release of histamine. A selective 5-HT1A receptor antagonist, WAY-100135, suppressed stimulation of histamine release by 5-HT or 8-hydroxy-PIPAT. Mast cell-stabilizing drugs, doxantrazole and cromolyn sodium, suppressed the release of histamine evoked by 5-HT or 8-hydroxy-PIPAT in guinea pig and human preparations. Our results support the hypothesis that serotonergic degranulation of enteric mast cells and release of preformed mediators, including histamine, are mediated by the 5-HT1A serotonergic receptor. Association of 5-HT with the pathophysiology of functional gastrointestinal disorders (e.g., irritable bowel syndrome) underlies a question of whether selective 5-HT1A receptor antagonists might have therapeutic application in disorders of this nature.
血清素[5-羟色胺(5-HT)]从小肠黏膜的肠嗜铬细胞中释放。我们检验了一个假设,即肠嗜碱性粒细胞环境中 5-HT 的升高可能会脱颗粒化嗜碱性粒细胞,并释放介质,这些介质成为旁分泌信号,作用于肠神经系统、脊髓传入神经和分泌腺。使用 Western blot、免疫荧光、ELISA 和药理学分析来研究小肠和 Roux-en-Y 胃旁路手术中丢弃的人空肠段中肠嗜碱性粒细胞 5-HT 受体的表达以及 5-HT 对脱颗粒化嗜碱性粒细胞和释放组胺的作用。人和豚鼠制剂中的嗜碱性粒细胞表达 5-HT1A 受体。ELISA 检测到豚鼠和人制剂中组胺的自发释放。选择性 5-HT1A 受体激动剂 8-羟基-PIPAT 引发组胺释放。选择性 5-HT1A 受体拮抗剂 WAY-100135 抑制 5-HT 或 8-羟基-PIPAT 刺激组胺释放。肥大细胞稳定剂 doxantrazole 和 cromolyn sodium 抑制 5-HT 或 8-羟基-PIPAT 在豚鼠和人制剂中诱发的组胺释放。我们的结果支持这样的假设,即肠嗜碱性粒细胞的 5-HT 脱颗粒化和预先形成的介质(包括组胺)的释放是由 5-HT1A 血清素受体介导的。功能性胃肠道疾病(例如,肠易激综合征)的病理生理学与 5-HT 相关,这引发了一个问题,即选择性 5-HT1A 受体拮抗剂是否可能在这种性质的疾病中具有治疗应用。